Generar recomendaciones basadas en la mejor evidencia disponible acerca de la prevención y tratamiento de Enfermedad Meningocócica.
Toda persona, niño o adulto, con sospecha o diagnóstico de Enfermedad Meningocócica, atendidos en cualquiera de los niveles de atención, ambulatorios y hospitalizado...
McGill, F;
Heyderman, RS;
Michael, BD;
Defres, S;
Beeching, NJ;
Borrow, R;
Glennie, L;
Gaillemin, O;
Wyncoll, D;
Kaczmarski, E;
Nadel, S;
Thwaites, G;
Cohen, J;
Davies, NW;
Miller, A;
Rhodes, A;
Read, RC;
Solomon, T.
Bacterial meningitis and meningococcal sepsis are rare conditions with high case fatality rates. Early recognition and prompt treatment saves lives. In 1999 the British Infection Society produced a consensus statement for the management of immunocompetent adults with meningitis and meningococcal sepsis. ...
Soins de réanimation,
Méningite bactérienne,
Infections à méningocoques,
Neisseria meningitidis,
Sepsie,
Ponction lombaire,
Sepsie/thérapie,
Sepsie/diagnostic,
Méningite bactérienne/diagnostic,
Méningite bactérienne/thérapie,
Infections à méningocoques/diagnostic,
Infections à méningocoques/thérapie
Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose serie...
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®...
Two meningococcal vaccines, MenACWY-D and Hib-MenCY-TT, were licensed for use in infants in April 2011 and June 2012, respectively. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods[1]. The primary policy question was “Should men...
Optimizar el manejo clínico de la EMI en la población infantojuvenil, con recomendaciones orientadas a lograr la detección precoz y una rápida instauración del tratamiento que permitan reducir la elevada morbilidad y mortalidad asociadas a la enfermedad; Ofrecer a los profesionales sanitarios que de...
